Royal Dutch Shell Plc & GlaxoSmithKline plc: Brilliant Bargains Or Value Traps?

Royston Wild considers whether bargain chasers should snap up Royal Dutch Shell Plc (LON: RDSB) and GlaxoSmithKline plc (LON: GSK).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Today I am looking at two FTSE 100 giants attracting the attention of value hunters.

Energy pick a risk too far

As supply/demand dynamics across the oil industry continues to worsen, I believe Royal Dutch Shell (LSE: RDSB) can be considered a bona-fide value trap at the present time.

Just today Investec slashed its Brent forecasts for 2016 and beyond. The broker now expects an average Brent price of $54 per barrel for 2015 to slump to $40 in the current period, before rising to $50 next year. A long-term forecast of just $55 is currently on the table.

However, even these forecasts may be considered a tad heady given the current direction of oil prices — Brent has skidded to fresh lows since 2004 around $32 per barrel in recent days. Indeed, Goldman Sachs’ $20 per barrel near-term target is becoming all the more likely as global production heads steadily higher and economic cooling saps demand.

Although Shell is trying to offset these problems by slashing costs and selling assets, I believe the producer remains a risk too far for savvy investors, as the structural supply changes needed to push earnings higher again will take some time to achieve.

Earnings are expected to have slipped 42% in 2015, although a 7% uptick is anticipated for 2016. I would consider a recovery of any sorts a precarious prediction in the current climate, and a P/E rating of 12.2 times fails to reflect this.

The dividend is expected to be cut to around 180 US cents per share for 2015 and 2016, down from 188 US cents in 2014 but still yielding a handsome 7.7%. But I believe dividend seekers should expect even larger payout reductions given Shell’s collapsing earnings outlook and hulking debt levels.

Drugs darling set to surge

Medicines giant GlaxoSmithKline (LSE: GSK) is certainly not without peril itself. The impact of revenues-crushing patent losses is set to linger a little while longer, while the often hit-and-miss nature of drugs development also means that future earnings are far from guaranteed.

But with GlaxoSmithKline’s renewed development drive resulting in a steady string of product approvals, and the business making shrewd acquisitions in hot growth areas to boost its long-term pipeline, I reckon investors can expect stellar returns in the coming years.

And with surging healthcare demand in emerging market bolstering the fruits of these endeavours still further, GlaxoSmithKline is expected to bounce back from four successive earnings declines with a 10% bounce in 2016. Such a figure leaves the drugs play dealing on a very-reasonable P/E rating of 15.8 times.

On top of this, GlaxoSmithKline’s vow to shell out a dividend of 80p per share through to 2017 creates a jumbo yield of 5.8%. I fully expect the Brentford business to make good on these intentions as its next generation of earnings drivers take off, and anticipate payouts to trek higher again in the years ahead.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and Royal Dutch Shell B. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A senior man and his wife holding hands walking up a hill on a footpath looking away from the camera at the view. The fishing village of Polperro is behind them.
Investing Articles

3 shares that could help a SIPP double in value

Christopher Ruane discusses a trio of FTSE 100 shares that he thinks investors should consider for their long-term potential to…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

I’ve doubled my money on this growth stock but I’m not selling it any time soon

Uber has been a great investment for Edward Sheldon, rising more than 100% in just two years. He believes the…

Read more »

British union jack flag and Parliament house at city of Westminster in the background
Investing Articles

The FTSE 100 is on fire! Yet these 2 stocks still look cheap to me

Despite the FTSE 100 hitting record highs, there’s no shortage of undervalued opportunities across the index, says Ben McPoland.

Read more »

Female student sitting at the steps and using laptop
Investing Articles

Greggs shares: an outstanding bargain after crashing nearly 40%?

Shares of one-time market darling Greggs have been in foul form recently. But is this a once-in-a-blue-moon opportunity for our…

Read more »

Close-up of children holding a planet at the beach
Investing Articles

This FTSE 100 stock’s suddenly become the highest-yielder on the index!

The league table of FTSE 100 (INDEXFTSE:UKX) dividend stocks has a new number one. But our writer explains why there…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

Is this under-the-radar UK stock as cheap as its rooms?

Our writer’s been keeping an eye on a little-known UK stock that operates in a niche, but profitable, sector of…

Read more »

Young Caucasian woman holding up four fingers
Investing Articles

It’s a ‘Fabulous Friday’ for holders of these FTSE 100 shares!

Four members of the FTSE 100 (INDEXFTSE:UKX) are making their latest dividend payments today (11 July). Our writer takes a…

Read more »

Man riding the bus alone
Investing Articles

Check out this spectacular FTSE 250 stock

UK investors willing to look beyond the FTSE 100 can find some outstanding companies. Online advertising business Baltic Classifieds might…

Read more »